

Todd A Fehniger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6561229/todd-a-fehniger-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

159
papers

12,855
citations

46
h-index

113
g-index

173
ext. papers

15,104
ext. citations

6.2
avg, IF

6.07
L-index

#	Paper	IF	Citations
159	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.. <i>Science Translational Medicine</i> , 2022 , 14, eabm1375	17.5	2
158	A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 585-596	6.4	0
157	End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021 , 138, 3506-3506	2.2	1
156	Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1832-1832	2.2	
155	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. <i>Blood</i> , 2021 , 138, 194-194	2.2	
154	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. <i>Blood</i> , 2021 , 138, 3825-3825	2.2	
153	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2021 ,	2.2	2
152	Flow cytometry-based murine NK cell cytotoxicity assay. <i>STAR Protocols</i> , 2021 , 2, 100262	1.4	1
151	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3339-3350	12.9	7
150	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies. <i>Clinical Cancer Research</i> , 2021 , 27, 3744-3756	12.9	7
149	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4859-4869	12.9	5
148	Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. <i>Cell Reports</i> , 2021 , 35, 109209	10.6	4
147	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021 , 9, 1071-1087	12.5	7
146	A Systemic Protein Deviation Score Linked to PD-1 CD8 T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma.. <i>Med</i> , 2021 , 2, 180-195.e5	31.7	
145	Donor Memory-like NK cells Persist and Induce Remissions in Pediatric Patients with Relapsed AML after Transplant. <i>Blood</i> , 2021 ,	2.2	5
144	Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. <i>Cell Reports</i> , 2020 , 31, 107720	10.6	18
143	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. <i>Blood Advances</i> , 2020 , 4, 2387-2391	7.8	5

142	Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. <i>Developmental Cell</i> , 2020 , 53, 229-239.e7	10.2	25
141	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020 , 136, 2308-2318	2.2	55
140	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	27
139	A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 8-9	2.2	1
138	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
137	CD56 regulates human NK cell cytotoxicity through Pyk2. <i>ELife</i> , 2020 , 9,	8.9	12
136	Memory-like natural killer cells for cancer immunotherapy. <i>Seminars in Hematology</i> , 2020 , 57, 185-193	4	15
135	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2223-2228 ¹	4.7	1
134	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020 , 10, 1854-1871	24.4	30
133	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 740-754	7.8	19
132	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
131	Mystery Solved: IL-15. <i>Journal of Immunology</i> , 2019 , 202, 3125-3126	5.3	2
130	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. <i>Immunity</i> , 2019 , 51, 479-490.e6	32.3	22
129	Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2019 , 134, 1954-1954	2.2	11
128	Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Blood</i> , 2019 , 134, 3307-3307	2.2	8
127	Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. <i>Blood</i> , 2019 , 134, 869-869	2.2	1
126	Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. <i>Blood</i> , 2019 , 134, 3237-3237	2.2	2
125	System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. <i>Blood</i> , 2019 , 134, 2897-2897	2.2	

124	Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. <i>Blood</i> , 2019 , 134, 2464-2464	2.2	
123	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019 , 134, 1550-1550	2.2	
122	Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-12	5.2	4
121	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018 , 131, 2515-2527	2.2	194
120	Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	7
119	A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1581-1589	4.7	38
118	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. <i>Haematologica</i> , 2018 , 103, e270-e273	6.6	1
117	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 357-362	1.9	6
116	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018 , 131, 182-190	2.2	92
115	Comment on: Evidence of innate lymphoid cell redundancy in humans. <i>Nature Immunology</i> , 2018 , 19, 788-789	19.1	5
114	Loss-of-Function Mutations Derepress ASH1L to Increase Gene Expression and Promote Leukemogenesis. <i>Cancer Research</i> , 2018 , 78, 3510-3521	10.1	17
113	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018 , 132, 2929-2929		
112	Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. <i>Blood</i> , 2018 , 132, 1271-1271		
111	A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nature Genetics</i> , 2018 , 50, 1735-1743	36.3	38
110	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718	7.8	9
109	Transcriptional and post-transcriptional regulation of NK cell development and function. <i>Clinical Immunology</i> , 2017 , 177, 60-69	9	19
108	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 648-653	4.7	28
107	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 398-404	4.7	40

106	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017 , 129, 473-483	2.2	98
105	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1	359
104	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , 2017 , 6, 2814-2821	4.8	11
103	CD70 turns on NK cells to attack lymphoma. <i>Blood</i> , 2017 , 130, 238-239	2.2	1
102	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2017 , 133, 61-77	14.3	52
101	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. <i>JCI Insight</i> , 2017 , 2,	9.9	58
100	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. <i>Journal of Clinical Investigation</i> , 2017 , 127, 4042-4058	15.9	131
99	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 347-353	2	19
98	The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016 , 22, 596-608	12.9	97
97	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016 , 375, 2023-2036	59.2	493
96	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. <i>Science Translational Medicine</i> , 2016 , 8, 357ra123	17.5	403
95	Harnessing NK Cell Memory for Cancer Immunotherapy. <i>Trends in Immunology</i> , 2016 , 37, 877-888	14.4	58
94	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1851-1860	4.7	91
93	Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. <i>Blood</i> , 2016 , 128, 5285-5285	2.2	
92	Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. <i>Blood</i> , 2016 , 128, 3419-3419 ^{2.2}		
91	Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. <i>Blood</i> , 2016 , 128, 550-550	2.2	
90	The Use of CD34+-Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2016 , 128, 4697-4697	2.2	
89	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016 , 101, e465-e468	6.6	32

88	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1696-1701	4.7	44
87	Human Adaptive Natural Killer Cells: Beyond NKG2C. <i>Trends in Immunology</i> , 2016 , 37, 351-353	14.4	16
86	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 211-8	3.6	35
85	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1425-30	4.7	9
84	Human Cytokine-Induced Memory-Like Natural Killer Cells. <i>Journal of Innate Immunity</i> , 2015 , 7, 563-71	6.9	51
83	MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. <i>Journal of Immunology</i> , 2015 , 195, 2806-17	5.3	37
82	Memory NK Cells Take Out the (Mitochondrial) Garbage. <i>Immunity</i> , 2015 , 43, 218-20	32.3	2
81	Improving natural killer cell cancer immunotherapy. <i>Current Opinion in Organ Transplantation</i> , 2015 , 20, 671-80	2.5	34
80	PTEN regulates natural killer cell trafficking in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E700-9	11.5	28
79	Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 101-101	2.2	3
78	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , 2015 , 126, 1950-1950	2.2	4
77	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15R α Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. <i>Blood</i> , 2015 , 126, 1957-1957	2.2	7
76	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3988-3988	2.2	5
75	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015 , 126, 574-574	2.2	2
74	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015 , 126, 689-689	2.2	1
73	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015 , 126, 3144-3144	2.2	2
72	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. <i>Blood</i> , 2015 , 126, 3106-3106	2.2	
71	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 46-52	4.7	72

70	microRNA management of NK-cell developmental and functional programs. <i>European Journal of Immunology</i> , 2014 , 44, 2862-8	6.1	33
69	Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 463-73	4.7	15 ⁸
68	Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. <i>Scientifica</i> , 2014 , 2014, 205796	2.6	82
67	Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 1117-1117	2.2	7
66	Preliminary Results of a Phase 1/2 Clinical Trial of Cnd0-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. <i>Blood</i> , 2014 , 124, 2320-2320	2.2	5
65	A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2014 , 124, 3099-3099	2.2	3
64	The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody. <i>Blood</i> , 2014 , 124, 807-807	2.2	2
63	PTEN Regulates Natural Killer Cell Trafficking in Vivo. <i>Blood</i> , 2014 , 124, 753-753	2.2	
62	MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. <i>Journal of Immunology</i> , 2013 , 191, 5904-13	5.3	47
61	Lenalidomide-mediated enhanced translation of C/EBP β 30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 159-69	2.2	53
60	"AbroGATAed" human NK cell development. <i>Blood</i> , 2013 , 121, 2579-80	2.2	1
59	Extracellular microRNAs turn on NK cells via TLR1. <i>Blood</i> , 2013 , 121, 4612-3	2.2	5
58	MicroRNA regulation of natural killer cells. <i>Frontiers in Immunology</i> , 2013 , 4, 44	8.4	39
57	Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. <i>Blood</i> , 2013 , 122, 17-17	2.2	3
56	IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells. <i>Blood</i> , 2013 , 122, 2283-2283		3
55	Human Cytokine-Induced Memory-Like (CIML) NK Cells Exhibit Potent Anti-Leukemia Cytotoxicity and Maintain Memory-Like Functionality After Adoptive Transfer Into Immunodeficient NOD-SCID-Gc $^{-/-}$ (NSG) Mice. <i>Blood</i> , 2013 , 122, 4501-4501	2.2	1
54	MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. <i>Journal of Immunology</i> , 2012 , 188, 3019-30	5.3	51
53	Natural killer cell regulation by microRNAs in health and disease. <i>Journal of Biomedicine and Biotechnology</i> , 2012 , 2012, 632329		20

52	Cytokine activation induces human memory-like NK cells. <i>Blood</i> , 2012 , 120, 4751-60	2.2	344
51	T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 937-43	4.7	21
50	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 1623-1623	2.2	5
49	A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012 , 120, 1644-1644	2.2	5
48	Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells. <i>Blood</i> , 2012 , 120, 3291-3291	2.2	
47	Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells.. <i>Blood</i> , 2012 , 120, 2159-2159	2.2	0
46	Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1646-52	4.7	76
45	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1828-33	2.2	95
44	Human NK cells: SET to kill. <i>Blood</i> , 2011 , 117, 2297-8	2.2	10
43	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011 , 118, 5119-25	2.2	152
42	MicroRNA-Deficient Murine NK Cells Exhibit Impaired Development and Survival but Enhanced IFN- γ Production In Vitro and In Vivo. <i>Blood</i> , 2011 , 118, 357-357	2.2	1
41	Next-generation sequencing identifies the natural killer cell microRNA transcriptome. <i>Genome Research</i> , 2010 , 20, 1590-604	9.7	111
40	Latent herpesvirus infection arms NK cells. <i>Blood</i> , 2010 , 115, 4377-83	2.2	58
39	Complete characterization of the microRNAome in a patient with acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 5316-26	2.2	56
38	Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. <i>Blood</i> , 2010 , 115, 1669-77	2.2	24
37	The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B. <i>Blood</i> , 2010 , 116, 104-104	2.2	
36	Differential expression of granzyme B and C in murine cytotoxic lymphocytes. <i>Journal of Immunology</i> , 2009 , 182, 6287-97	5.3	27
35	Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. <i>Blood</i> , 2009 , 113, 1002-5	2.2	64

34	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 3417-3417	2.2	3417	1
33	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3693-3693	2.2		9
32	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , 2009 , 114, 842-842	2.2		4
31	Comprehensive Evaluation of MicroRNA Genes and Gene Expression Using Next Generation Sequencing in a Patient with Acute Myelogenous Leukemia.. <i>Blood</i> , 2009 , 114, 271-271	2.2		1
30	Latent Murine Herpesvirus-4 Infection Arms NK Cells.. <i>Blood</i> , 2009 , 114, 3678-3678	2.2		
29	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008 , 112, 2595-2595	2.2		6
28	Chronic lymphocytosis of functionally immature natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 120, 924-31	11.5		5
27	Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. <i>Immunity</i> , 2007 , 26, 798-811	32.3		311
26	Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. <i>Immunity</i> , 2007 , 27, 635-46	32.3		543
25	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. <i>Blood</i> , 2007 , 110, 916-916	2.2		6
24	In Vivo Murine Cytokine Models and the Genesis of Cancer 2007 , 199-209			
23	Hop cleavage and function in granzyme B-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2006 , 281, 37130-41	5.4		16
22	Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors.. <i>Blood</i> , 2006 , 108, 920-920	2.2		
21	NK cell and DC interactions. <i>Trends in Immunology</i> , 2004 , 25, 47-52	14.4		361
20	New directions in natural killer cell-based immunotherapy of human cancer. <i>Expert Opinion on Biological Therapy</i> , 2003 , 3, 237-50	5.4		27
19	Biology and clinical impact of human natural killer cells. <i>International Journal of Hematology</i> , 2003 , 78, 7-17	2.3		80
18	CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. <i>Blood</i> , 2003 , 101, 3052-7	2.2		664
17	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. <i>Blood</i> , 2002 , 100, 3633-8	2.2		341

16	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002 , 100, 1935-47	2.2	405
15	Interleukin-2 and interleukin-15: immunotherapy for cancer. <i>Cytokine and Growth Factor Reviews</i> , 2002 , 13, 169-83	17.9	223
14	Natural killer cells: biology and application in stem-cell transplantation. <i>Cytotherapy</i> , 2002 , 4, 445-6	4.8	16
13	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002 , 8, 2812-9	12.9	31
12	Interleukin 15: biology and relevance to human disease. <i>Blood</i> , 2001 , 97, 14-32	2.2	758
11	The biology of human natural killer-cell subsets. <i>Trends in Immunology</i> , 2001 , 22, 633-40	14.4	2075
10	Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2001 , 193, 219-31	16.6	292
9	Fatal leukemia in interleukin-15 transgenic mice. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 223-30	2.1	39
8	Ontogeny and expansion of human natural killer cells: clinical implications. <i>International Reviews of Immunology</i> , 2001 , 20, 503-34	4.6	26
7	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. <i>Blood</i> , 2001 , 97, 3146-51	2.2	1023
6	Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. <i>Journal of Immunology</i> , 2000 , 164, 1643-7	5.3	58
5	Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2000 , 106, 117-24	15.9	76
4	Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. <i>Cancer Immunology, Immunotherapy</i> , 1998 , 46, 318-26	7.4	66
3	Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15. <i>Blood</i> , 1998 , 92, 3647-3657	2.2	176
2	Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells In Vivo. <i>Blood</i> , 1997 , 90, 3647-3653	2.2	31
1	CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. <i>European Journal of Immunology</i> , 1997 , 27, 354-60	6.1	90